Myriad Genetics (MYGN) Tops Q2 EPS by 4c

Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• Seacoast Banking Corporation of Florida (SBCF) Tops Q1 EPS by 2c
• ResMed (RMD) Tops Q3 EPS by 20c